Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Outcomes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There is no common rule as to how a drug will affect patients. This is due to the effect specific DNA sequences of genes have on drug response, by the effect they have on how medications are metabolized. The primary objective of this research is to optimize medication therapy and to reduce the number of medications used, specifically medications for people with developmental disabilities and co-occuring psychiatric illnesses.
| Condition | Intervention | Phase |
|---|---|---|
|
Developmental Disabilities |
Genetic: Genetic analysis |
Phase 4 |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Subject Outcomes |
saliva
| Estimated Enrollment: | 50 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Psychiatric illnesses
Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.
|
Genetic: Genetic analysis
The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
Other Name: pharmacogenomics
|
Detailed Description:
The primary goal of this study is to develop a process for utilizing pharmacogenomic analysis as a strategy to improve the quality of life, safety, decrease medication burden, and enhance the effectiveness of medications in people with psychiatric illnesses and developmental disabilities. Ultimately, this inter-disciplinary service could be developed into a standard screening and consultation tool for healthcare providers to utilize when determining the most appropriate medication for their patients.
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The study participants will all reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental diabilities and co-occuring psychiatric disorders.
Inclusion Criteria:
- Current resident of the South Dakota Developmental Center (SDDC)
- Currently taking a high number of medications per month
- Eligibility of the subjects will be determined by the treatment team which consists of 3-4 of the following individuals: treating psychologist, behavior therapist, case manager, supervisors, counselors, dietitians, physician assistants, occupational therapists, and physical therapists
Exclusion Criteria:
- To be determined by the research staff
Contacts and Locations More Information
Publications:
| Responsible Party: | Avera McKennan Hospital & University Health Center |
| ClinicalTrials.gov Identifier: | NCT01274065 History of Changes |
| Other Study ID Numbers: | ARI-1290-Pharm |
| Study First Received: | January 7, 2011 |
| Last Updated: | May 31, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Avera McKennan Hospital & University Health Center:
|
psychiatry psychiatric illness developmental disability mental health medication burden |
Additional relevant MeSH terms:
|
Developmental Disabilities Mental Disorders Diagnosed in Childhood Mental Disorders |
ClinicalTrials.gov processed this record on October 18, 2012
